Oern Stuge

About Oern Stuge

Oern Stuge is an international life sciences executive and serves as a director of MEDIAN Technologies. Trained as a physician, with an MD from the University of Oslo and an MBA from IMD Lausanne, he has built a career spanning more than 30 years at the crossroads of healthcare, innovation, and corporate development. He began his career in clinical practice before moving into senior leadership roles across major healthcare companies. At Medtronic, where he spent 12 years, Stuge held a series of senior executive positions, including Senior Vice President and President of EMEA, Canada and Emerging Markets, as well as SVP and President of Cardiac Surgery. He was also a member of Medtronic’s Executive Committee and Operating Committee. In these roles, he led a major transformation of Medtronic’s global cardiac surgery business, contributing to the creation of the Structural Heart Division and the launch of the world’s first commercially available percutaneous heart valve, a significant milestone in cardiovascular medical technology. Before Medtronic, he held senior positions at Abbott Laboratories and also served as CEO of a Norwegian start-up, giving him experience in both large-scale multinational organizations and entrepreneurial, high-growth environments. He is currently Chairman of Orsco Lifesciences AG, through which he holds several executive and non-executive board seats and advisory roles. According to MEDIAN Technologies’ published profile, over the last nine years he has participated in the development of multiple companies and successfully realized several exits through acquisitions or public listings. At MEDIAN Technologies, this background supports a governance approach focused on strategic growth, value creation, and operational discipline. His expertise includes corporate strategy, business transformation, international operations, and guiding innovative life sciences companies through complex development paths. This is particularly relevant for MEDIAN, a company active in medical imaging, artificial intelligence, and software used to support diagnosis and oncology clinical development, where scientific credibility, operational execution, and the ability to navigate regulatory and capital markets milestones are critical.